SHANGHAI – Zai Labs Ltd., of Shanghai, nabbed greater China rights for FPA-144, a first-in-class fibroblast growth factor (FGF) monoclonal antibody for gastric and gastroesophageal junction cancer being developed globally by Five Prime Therapeutics Inc., of San Francisco.